|
|
AS15 |
|
Vaxjo ID |
390 |
|
Vaccine Adjuvant Name |
AS15 |
|
Alternative Names |
AS15 is sometimes referred to as a combination adjuvant system consisting of MPLA and CpG oligonucleotides. |
|
Description |
AS15 is an adjuvant system composed of monophosphoryl lipid A (MPLA), QS21 saponin, and CpG oligonucleotide, formulated in a liposomal delivery system. It is designed to enhance immune responses in vaccines. |
|
Stage of Development |
Clinical Trial |
|
Host Species for Testing |
2 |
|
Structure |
 it consists of MPLA, QS21, and CpG components. |
|
Preparation |
AS15 is prepared by combining its components (MPLA, QS21, and CpG) in a liposomal formulation |
|
Function |
We highlight current vaccine adjuvants and the importance of immune synergies to adjuvant and vaccine design. The focus is on new technologies used to study and apply immune synergies to adjuvant and vaccine development. Finally, we discuss how recent findings can be applied to the future design and characterization of synergistic adjuvants and vaccines. Induces both humoral and cellular immune responses, and agonist of TLR3 and MDA5. |
|
Safety |
AS15 has shown a favorable safety profile in clinical applications, but specific safety data may vary based on the formulation and context of use. |
| References |
Kruit et al., 2013: Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013; 31(19); 2413-2420. [PubMed: 23715572].
Panigaj et al., 2023: Panigaj M, Skelly E, Beasock D, Marriott I, Johnson MB, Salotti J, Afonin KA. Therapeutic immunomodulation by rationally designed nucleic acids and nucleic acid nanoparticles. Frontiers in immunology. 2023; 14; 1053550. [PubMed: 36798121].
Tom et al., 2019: Tom JK, Albin TJ, Manna S, Moser BA, Steinhardt RC, Esser-Kahn AP. Applications of Immunomodulatory Immune Synergies to Adjuvant Discovery and Vaccine Development. Trends in biotechnology. 2019; 37(4); 373-388. [PubMed: 30470547].
|
|
